Nearly two full years into the COVID-19 pandemic, researchers are still in the process of learning what’s really going on inside the heads of…
UPDATE: 3 March 2024, 8:35 P.M. ET. In February 2024, Biogen took Aduhelm off the market, citing financial concerns. Although the drug did receive…
Looking for brain fog remedies? Neurological experts offer six ways to speed up recovery from COVID-19’s neurological symptoms. Memory problems. Trouble focusing. Confusion. Mounting…
Vaccines are one of the greatest medical advances in history. This strategy is now being applied to the treatment and prevention of Alzheimer’s. We…
Scientists have their eyes set on spotting Alzheimer’s early. The earlier the disease can be diagnosed, the better the chance that a combination of…
On the brink of a new year, a note from Being Patient Founder and Editor-in-Chief Deborah Kan. Dear readers, As I reflect on 2021,…
Alzheimer’s is a notoriously difficult disease to identify with certainty. By the time a patient receives a diagnosis, its pathology in the brain is…
Protollin, a new vaccine for Alzheimer’s that is administered nasally, heads to human clinical trials. Through the incredible power of our immune system, researchers…
Roughly two thirds of Americans with Alzheimer’s are women, but it isn’t exactly clear why the disease disproportionately impacts females. Given that age is…
Beta-amyloid plaques are a hallmark of Alzheimer’s, but researchers have long been puzzled about why these plaques can also be found in the brains…
New clinical trials on memory loss interventions are currently enrolling healthy participants with key Alzhemier’s biomarkers as young as 55 years old. Tau and…
Despite the absence of disease-modifying treatments, the dementia rate in developed Western countries has actually declined in recent years. In fact, one study showed…
You may have read about it in the New York Post: “Scientists pinpoint personality traits that increase risk of Alzheimer’s.” A recent study published in…
The amyloid hypothesis—the idea that Alzheimer’s is caused by clumps of proteins known as beta-amyloid—remains unproven. But scientists are holding out hope that monoclonal…
The biotechnology company Eisai Co., Ltd. announced a rolling submission for accelerated approval from the Food and Drug Administration for their anti-amyloid Alzheimer’s treatment,…